From Monday, March 28, 2022 the antiviral drug for COVID-19 Nirmatrelvir / Ritonavir (PAXLOVID®, PFIZER) will be available and will apply for applications that will be submitted from tomorrow, Friday, March 25.
A similar procedure will be followed for the disposal of molnupiravir (LAGEVRIO).
The antiviral drug is given for the first 5 days after the onset of symptoms.
The application for the drug is made in the first 3 days after the onset of symptoms and after confirmation of COVID-19 infection with rapid antigen (RAPID) or molecular (PCR) test.
The consent of the patient is not required, but the patient is required to have an intangible prescription, because after the approval of the application, the treating physician must prescribe the drug (from the electronic prescribing platform, with the usual procedure).
The drug is administered to adults and children> 12 years old weighing more than 40 Kg. Not for use during pregnancy and lactation, in dialysis patients and in patients with severe renal impairment (creatinine clearance
Due to the potential for interactions between ritonavir and PAXLOVID®’s already receiving patient medications, it is recommended that all patient medications interact with the treating physician, using the https link: //www.covid19-druginteractions.org/.
Attention is also drawn to the presence of risk factors for the development of a serious disease, which are the following:
• Transplantation of solid organs or hematopoietic cells
• People on a waiting list for an organ transplant
• Cystic fibrosis
• Solid organ cancer in people undergoing treatment (chemotherapy, radiotherapy, immunotherapy or other treatment)
• Hematological malignancies (active disease)
• Primary immunodeficiencies & 2-patients due to treatment with B-specific agents e.g. Rituximab, high doses and prolonged administration of corticosteroids, biological agents
• HIV with CD4
• Age ≥75 years
• 2 or more factors from the following:
o Age ≥ 65
o BMI ≥ 35
o SD under treatment
Chronic kidney disease (creatinine clearance> 30ml / min for Paxlovid)
Chronic liver disease
Chronic cardiovascular disease (stroke, heart attack, heart failure, peripheral vascular disease, aneurysms, AV under treatment)
o Pulmonary fibrosis
Chronic respiratory failure under oxygen therapy
Thalassemia, sickle cell disease
Follow Skai.gr on Google News
and be the first to know all the news
